Fascioliasis Infections and Infestations Other fluke infections
Conditions
Interventions
This trial consisted of two separate single-arm studies. Study 1 and 2 involved different subjects.
Study 1: 22 patients were given 80 mg artemether (oral) twice daily for 3 days
Study 2: 19 patient
Sponsors
Swiss Tropical Institute (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, age 11-70 years 2. For married females, not pregnant, as assessed by the medical doctor last menstrual cycle, upon initial clinical assessment 3. Absence of major systemic illnesses, as assessed by the medical doctor, upon initial clinical assessment 4. Infection with F. hepatica and/or F. gigantica as confirmed by standard parasitological stool examination 5. No known or reported hypersensitivity to artemether 6. No known or reported history of chronical illness such as cancer, diabetes, hypertension, chronic heart, liver or renal disease 7. Full clinical examination 8. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Presence of any abnormal medical condition, judged by the medical doctor. If several patients experience serious adverse events the study will be stopped. 2. Severe liver disease of other aetiology 3. Recent history of anthelminthic drugs (triclabendazole, albendazole, bithionol, dehydroemetine, praziquantel within past 4 weeks) 4. Attending other clinical trials during the study 5. For females: pregnancy, lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate and egg reduction rate at 28 days post treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events. Patient were monitored for 3 hours after each dose. | — |
Countries
Egypt
Outcome results
None listed